CD8A and systemic sclerosis: Immunohistochemical analysis showed that BM-MSC-EV treatment significantly reduced the infiltration of inflammatory cells, such as F4/80+ macrophages and CD4+/CD8+ lymphocytes, in a mouse model of SSc.